ArticleDevelopmental cell2016
Hippo Wades into Cancer Immunology.
Article in Developmental cell, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Exosomes derived from ITGB1 modified Telocytes alleviates LPS-induced inflammation and oxidative stress through YAP1/ROS axis.Heliyon · 2024Article
- YAP1 is a Prognostic Biomarker and Correlated with Immune Cell Infiltration in Pancreatic Cancer.Frontiers in molecular biosciences · 2021Article
- YAP Attenuates CD8 T Cell-Mediated Anti-tumor Response.Frontiers in immunology · 2020Article
- Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC).International journal of molecular sciences · 2019Review
- Metformin attenuates PD-L1 expression through activating Hippo signaling pathway in colorectal cancer cells.American journal of translational research · 2019Article
- The Role of Yes-Associated Protein (YAP) in Regulating Programmed Death-Ligand 1 (PD-L1) in Thoracic Cancer.Biomedicines · 2018Review
- YAP regulates PD-L1 expression in human NSCLC cells.Oncotarget · 2017Article
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Hippo pathway limits organ size and suppresses tumors. Reporting in Cell, Moroishi et al. (2016), show that, paradoxically, Hippo pathway inactivation can repress tumor growth by modulating tumor immunogenicity. This could explain the rarity of pathway mutations in cancers and suggests Hippo pathway repression as a cancer immunotherapy modality.
Indexed as
Identifiers
27997822What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.